Kymera Therapeutics (KYMR) Rule 144 notice for RSU shares and prior sale

Rhea-AI Filing Summary

Kymera Therapeutics submitted a Rule 144 notice for proposed sales of common stock, including 5,613 shares and 5,000 shares acquired upon RSU vesting.

The filing shows the 5,613 shares were acquired on 03/01/2026 and the 5,000 shares were acquired on 03/03/2026, both under the 2020 Equity Incentive Plan. It also reports prior sales of 49,307 shares on 12/08/2025 for aggregate proceeds of $3,284,832.34.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:08 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza 38th Floor New York NY 10004	10613	956231	81642394	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2026	Shares acquired upon vesting of Restricted Stock Units awarded under the Issuer's 2020 Equity Incentive Plan.	KYMERA THERAPEUTICS, INC.			5613	03/01/2026	Equity compensation
Common Stock	03/03/2026	Shares acquired upon vesting of Restricted Stock Units awarded under the Issuer's 2020 Equity Incentive Plan.	KYMERA THERAPEUTICS, INC.			5000	03/03/2026	Equity compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	Common Stock	12/08/2025	49307	3284832.34

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Kymera Therapeutics' (KYMR) Form 144 disclose?

It discloses proposed sales of common stock under Rule 144. The notice lists proposed sales of 5,613 shares (03/01/2026) and 5,000 shares (03/03/2026) acquired upon RSU vesting under the 2020 Equity Incentive Plan, plus a prior sale of 49,307 shares.

How many shares were sold previously according to the KYMR filing?

49,307 shares were sold on 12/08/2025. The filing reports aggregate proceeds from that sale of $3,284,832.34, listed in the "Securities Sold During The Past 3 Months" section of the notice.

What acquisition method is tied to the shares in the KYMR Form 144?

The shares were acquired upon vesting of Restricted Stock Units. The filing states the 5,613 and 5,000 shares were acquired upon RSU vesting under Kymera's 2020 Equity Incentive Plan on 03/01/2026 and 03/03/2026.

Which broker is listed in the Kymera (KYMR) Form 144?

Morgan Stanley Smith Barney LLC is the listed broker-dealer. The filing names the firm with addresses at 1 New York Plaza in New York as the intermediary associated with the reported transactions.

Does the KYMR Form 144 state proceeds for the proposed sales of 5,613 and 5,000 shares?

No proceeds are stated for the proposed sales in the provided excerpt. The filing shows acquisition dates and share counts for those RSU-vested shares; proceeds are listed only for the prior 49,307-share sale on 12/08/2025.